Пациенты в России жалуются на проблемы с доступностью зарубежных препаратов от рака грудиВ частности

Псковская Лента Новостей

Пациенты в России жалуются на проблемы с доступностью зарубежных препаратов от рака груди

В частности, зафиксированы факты отсутствия онкопрепаратов «Пикрэй» от швейцарской компании Novartis и «Абраксан» от американской Bristol Myers Squib.
Во Всероссийском союзе пациентов ситуацию связывают с отсутствием препаратов «Абраксан» и «Пикрэй» в перечне жизненно важных лекарственных препаратов (ЖНВЛП).

www.tg-me.com/ye/ПсковскаяЛентаНовостей/com.plnpskov/46791

3.0K viewsMay 22 at 06:11

tg-me.com/plnpskov/46791

Create: 2024-05-22
Last Update: 2024-06-20 17:47:40

BY Псковская Лента Новостей

Share with your friend now:
tg-me.com/plnpskov/46791

ПсковскаяЛентаНовостей Telegram | DID YOU KNOW?

That strategy is the acquisition of a value-priced company by a growth company. Using the growth company's higher-priced stock for the acquisition can produce outsized revenue and earnings growth. Even better is the use of cash, particularly in a growth period when financial aggressiveness is accepted and even positively viewed.he key public rationale behind this strategy is synergy - the 1+1=3 view. In many cases, synergy does occur and is valuable. However, in other cases, particularly as the strategy gains popularity, it doesn't. Joining two different organizations, workforces and cultures is a challenge. Simply putting two separate organizations together necessarily creates disruptions and conflicts that can undermine both operations.

To pay the bills, Mr. Durov is issuing investors $1 billion to $1.5 billion of company debt, with the promise of discounted equity if the company eventually goes public, the people briefed on the plans said. He has also announced plans to start selling ads in public Telegram channels as soon as later this year, as well as offering other premium services for businesses and users.